Get started

Pennystocks

Shiny Materials Penny Stocks fadingHi followers, After a long period of time, I finally get back on track to update some TA. In this January, I will highlight a few potential stocks to be considered. For those of you that hold these two penny stocks. They have both MA crossover on 17 Dec, hold your fire now since they almost hit the ceiling. SYR has a few bearish candlesticks signals, beware of the bomb! VectorVest values (10-Jan-2022) Mincor Rsrcs NL MCR RT = 1.76 RS = 0.93 VST = 1.24 CI = 1.23 REC = Buy Syrah Rsrcs SYR RT = 1.77 RS = 0.91 VST = 1.30 CI = 1.07 REC = Buy
M
by SoloTraderAU
$RBSH 350k Mrkt Cap, 9mil Float, Completed Turnaround Last Month$RBSH This has a 9mil Float, MM's walked it down on low Vol after a recent RS... Volume has come back with over 10x the 10Day Ave Vol, Accumulation out the roof, all indicators pointing to breakout soon... The Co just Completed a turnaround, New Officers Juts took over along with Ticker & Name Change...( Formerly Inspyr Therapeutics, now Rebus Holdings Inc ) They have Clinical Updates Coming, multiple patents, and also just reacquired some additional patents. See Link Below 15 U.S Patents, 40 Pending World Wide Applications - Clinical Trials Happening Currently - Google - inspyr-therapeutics-announces-holding-company-110000130 (Sorry, Can not post Link) So understand this - For this to have a $40 Million Market Cap which it did in 2021 - Now with the current SS, the price of $RBSH needs to be at $4 - Currently at $0.04 Cents = 1000% Up from here. No pumping needed, look into Inspyr. - FDA Meeting Held 2021 - Clinical Updates Coming - Inspyr had a market cap of 100 Million - Current market cap =350,000 - OS is 10 Million - Float - 9 Million Took positions .035-.04 so far, will add on .05 Break inspyrtherapeutics dot com rebus-corp dot com Patents + FDA Clinical Trials - Developing targeted cancer therapeutics that delivers a potent, unique & patented drug that directly treats breast, prostate, bladder, kidney, and lung cancer. Inspyr Therapeutics, Inc. is an integrated clinical-stage biopharmaceutical company focused on the development of targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer based on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark, Inspyr has a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. The pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company’s drug candidates within a tumor. Inspyr’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types. The company involves in the discovery and development of pro-drug cancer therapeutics. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its pro-drug development candidates include G-202, which is in Phase I clinical trials and targets the blood vessels of various solid tumors; and G-114, G-115, and Ac-GKAFRR-L12ADT, which are in pre-clinical animal models for the treatment of prostate cancer.
OTC:RBSHLong
by HDOGTX
BRGO Logscale Bullish ButterflyThe PCZ here is massive and because of that overall i wont be dedicating much of my account to this trade since this is a dangerous penny stock that shows no promise other than the potential logscale harmonic pattern presented on the chart; I personally will buy $500 worth at the 1.272, another $750 at the 1.414, and a final $1000 worth at the 1.618. I dont plan on using a stoploss for this trade which is why the amount i m going to invest is so low but in either case that's still alot of share so it's worth a shot.
OTC:BRGOLong
by RizeSenpai
LIVC to the MOON?? 🧑‍🚀Live Current Media has been working on a sport betting app. Company pivoted last year from a medical tech sales vendor. App is functional but not making any meaningful money yet. This stock has good support below .4 with a large petroleum/oil investor racking up between .3 and .4. Every time he posts his SEC purchase filing the stock takes back off. They have some assests in the form of owning website rights and sold one last year for around $1m I believe. Average trading volume is 195k/day - very low. Price swings of 5-15%/day. This is a penny stock with little to no income right now so obviously risky. I believe it is riding the wave of sports betting excitement but could lose support with little to no reason. Be Careful. I am not a financial advisor. Do your own research. Happy Trading!
LLong
by ZaphodBeebz
+5100 % return on MRIN stockFor risk-takers, this is for you, SAN FRANCISCO Marin Software, a leading provider of digital marketing software for performance-driven advertisers and agencies. by studying the company file we noticed... Volatility and Risk Marin Software has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500. Comparatively, Marin Software’s competitors have a beta of 1.37, meaning that their average share price is 37% more volatile than the S&P 500. Data from Investing.com Total Assets 37.01M (31/12/2020) 42.29M (31/12/2019) 46.79M (31/12/2018) 83.37M (31/12/2017) Decreasing rate % from the year before : -12.48 % 2020 -9.61 % 2019 - 43.87 % 2018 By looking on the cash situation Cash From Operating Activities -5.67 M -1.24 M -12.98 M -4.87M Cash From Investing Activities -1.88 M 1.61 M -2.71 M -2.52M Cash From Financing Activities 10.23 M 0.26 M -1.29 M -1.45M Net Change in Cash 2.71 M 0.60 M -17.33M -6.88 M Total Long Term Debt 1.47 M 0.01 M - 1.69M Dept ratio to assets 3.97 % 0.02 % - 2.02 % ========================================= Net Profit margin 5YA -37.01% (for the company) 15.7%( for the industry) Return on Assets 5YA -32.48% 9.13 % Return on Investment 5YA -40.57% 12.97 % ========================================= Price to Sales TTM 2.81 25.31 by looking to shareholders the top holders are Stockholder Stake Shares owned (data from CNN business) Susquehanna Financial Group LLLP 2.89% 447,414 Royce & Associates LP 2.80% 432,844 The Vanguard Group, Inc. 1.00% 154,543 Jane Street Capital LLC 0.81% 125,427 Schonfeld Strategic Advisors LLC 0.68% 105,600 Geode Capital Management LLC 0.63% 96,620 Nebula Research & Development LLC 0.41% 62,781 Bridgeway Capital Management LLC 0.39% 60,000 Cutler Group LP 0.35% 53,910 Dimensional Fund Advisors LP 0.34% 52,888 by reviewing the company file we express our opinion as MARIN is a high-risk good stock to buy even we can see the company file is not doing well, we can buy the dip of the company. Position ------------------ Buy limit order at 1$ - 1.5$ ------------------------- Targeting: ------------------------- 22 $ - 23$ as first target 51 $ - 53.5 $ as second target Investment period from 6 months to 18 months (estimated) We expect +2200% to +5100% return for 18 months
NASDAQ:MRINLong
by youssefallax
4
AMC: Allacciate le cinture!Prima che la bolla scoppi, bisogna darle benzina! 5a onda in arrivo: target 91 dollari Mi trovate in questi canali: ● 𝙏𝙚𝙡𝙚𝙜𝙧𝙖𝙢 (in privato) ➡️ @fantasyste ● 𝙂𝙧𝙪𝙥𝙥𝙤 𝙩𝙚𝙡𝙚𝙜𝙧𝙖𝙢 𝙞𝙣 𝙄𝙩𝙖𝙡𝙞𝙖𝙣𝙤 ➡️ 𝙝𝙩𝙩𝙥𝙨://𝙩.𝙢𝙚/𝙩𝙤𝙩𝙚𝙢𝙩𝙧𝙖𝙙𝙞𝙣𝙜 ● 𝙔𝙊𝙐𝙏𝙐𝘽𝙀 ➡️ 𝙗𝙞𝙩.𝙡𝙮/𝙩𝙤𝙩𝙚𝙢𝙔𝙊𝙐𝙏𝙐𝘽𝙀
NYSE:AMCLong
by fantasyste
$Enzc where do we go from here??? The chart broke down from our previous wedge, causing a wide broadening formation. We broke below the 0.618 fib level, would have liked to see a sustained volume shelf there creating a better support. Price will need to bounce from 0.1011 and close above that level or we will continue to see continued selling pressure. EXPECT ALOT OF VOLATILITY FOR THE REMAINDER OF DECEMBER! I still haven't sold a single share and will continue to aquire more every chance I get (seems more now than ever) Know your 50/30/20 rule! 50% of what a stock does is determined by what the overall market does 30% of what a stock does is determined by what the sector & industry group does 20% of the movement of the stock is determined by the analysis of the stock itself
OTC:ENZC
by OptionStonker
WISH - Possible a rebounce today. 1H chart RSI oversoldHi All, my main 3 take-outs from this analysis are the following: 1- The hourly chart shows RSI in oversold territory with high chances of a rebounce 2- Price might be retesting the resistence at arund 4.60$ in the next days 3- Still valid the possibility of an upward breakout of the descending wedge shown in the daily chart Not a financial advice, just personal opinion. Do your own due diligence and good luck!
WLong
by FrancescoMerlettini
3
#SNDL - The story might be repeating again...Hi All, my main 3 take-outs from this analysis are the following: 1- Price is moving as per historical recent moves 2- Price is still within the falling wedge and should see a breakout (hopefully upwards) prior getting to the apex. But it might take still some time 3- By tday and tomorrow we might possibly see a rebounce from the 0.66-0.65$ levels, as also shown in the past. Not a financial advice, just personal opinion. Do your own due diligence and good luck!
NASDAQ:SNDLLong
by FrancescoMerlettini
WISH - Moving in a descending wedge, possibly breaking up soon..Hi Guys, WISH is moving inside a falling wedge in the daily chart. Two third of this wedge is approximately end of January (blue box) where the price might realistically break the red trendline of resistence and reach the 6$. If this will happen, next price targets will be the 9$ gap filling and mostly the 15$ level, which represent the target given by the height of the same descending wedge. In addition to this, MACD on the daily chart is showing a huge bullish divergence which makes pretty realistic an inversion in the upcoming weeks. Not a financial advice, just personal opinion. Do your own due diligence and good luck!
WLong
by FrancescoMerlettini
3